ADDIT-CE NeuroConnect Meetup

CONNECT, SHARE, INNOVATE –
120 SECONDS AT THE FOREFRONT
OF ALZHEIMER'S AND
NEURODEGENERATIVE
DISEASES



5 November 2026
3:00 – 6:30 PM

MultiplexDX, Bratislava
Vedecký Park Univerzity Komenského

Presenter Catalogue

10 pitches · investor jury · Success Story panel

Multiplex DX

BioVendor Group®

JIC

BridgeTTe

MUNI

ADDIT-CE

Funded by the European Union

Program

Thursday 5 November 2026 · MultiplexDX, Comenius University Science Park, Ilkovičova 8, Bratislava

2:00 PM	Technical rehearsal For presenters and jury
2:30 – 3:00 PM	Registration
3:00 – 3:15 PM	Welcome & ADDIT-CE news
3:15 – 4:00 PM	Pitch block 1 · pitches 1–5 120-second pitch + questions from the investor jury
4:00 – 4:15 PM	Coffee & networking break
4:15 – 5:00 PM	Pitch block 2 · pitches 6–10 120-second pitch + questions from the investor jury
5:00 – 5:40 PM	Success Story panel Pavol Čekan & Petra Zahradníková, moderated by Radka Martínková
5:40 – 5:45 PM	Closing ceremony & best pitch award
5:45 – 6:30 PM	Informal networking & matchmaking

How a pitch slot works

2 min
The pitch. One presenter, one project, a countdown on the screen.

4 min
Questions from the investor jury.

How to use this catalogue

Profiles follow the order of the pitches. Each page shows what the project solves, how far it is and what the team is looking for. Contacts are on every page, so you can follow up right after the pitch or any time later.

Investor jury



Eva Šimeková

Partner – Startups & Investment, Disruption Embassy

With 20+ years at the intersection of startups, venture capital, and innovation, Eva helps founders build investable businesses and guides corporates and policymakers in turning bold ideas into real impact. She has mentored hundreds of founders, trained innovators, and built platforms connecting entrepreneurs, corporates, and science.

linkedin.com/in/eva-šimeková-a182285



Terézia Jacová

Co-Founder, Lumus Investment Collective

Terézia is the Co-Founder of Lumus Investment Collective, a club for female angel investors backing CEE tech startups. She also serves as an external expert for the European Innovation Council.

“The best investment isn’t just the one that grows on your account – it’s the one that grows in your knowledge and relationships.”


linkedin.com/in/terezia-jacova-39401737

Best pitch award

The best pitch wins a free consultation with one of the investors. Every presenter receives a certificate of participation.

Success Story panel

What does it take to get from a lab result to a product people pay for? Two founders who have done it share what worked, what did not and what they would do differently.



Dr. Pavol Čekan

Founder and CEO, MultiplexDX

After twenty years abroad – in Iceland, at Rockefeller University in New York and at the National Cancer Institute – Pavol came home and founded MultiplexDX, the first Slovak company ever to win the EIC Accelerator.



Assoc. Prof. Petra Zahradníková, MD, PhD, MPH

Paediatric surgeon, Faculty of Medicine, Comenius University / NÚDCH · Co-founder, InfantSim

Petra operates on newborns who sometimes weigh less than a kilogram. Because the right training tool didn't exist, she decided to build it: her start-up InfantSim has developed a 3D-printed simulator for keyhole surgery on newborns and has been selected for the EIC Pre-Accelerator.



Radka Martínková · moderator

Independent consultant (Wild Witch) at the intersection of business, technology and science, with 20+ years in international B2B sales, business development and community building. She helps researchers present their work to investors and partners.

Pitches at a glance

#	PRESENTER	AREA	STAGE	LOOKING FOR	PAGE
01	**David Damborský** Loschmidt Laboratories, Masaryk University	Research tools & platforms	Proof of concept in the lab	Industrial / co-development partner · Research collaboration · Business mentoring	6
02	**Sarah Anne Barnes** MultiplexDX International	Research tools & platforms	Validated prototype / preclinical	Investment · Industrial / co-development partner · Business mentoring	7
03	**Ondrej Cehlár** Institute of Neuroimmunology SAS	Research tools & platforms	Clinical validation / pilot with users	Research collaboration	8
04	**Katarína Kiseľáková** Slovenská Alzheimerova spoločnosť	Family and patients support	On the market	Investment · Research collaboration · Business mentoring	9
05	**Jozef Hritz** CEITEC/SciF, Masaryk University	Structural Biology & Biophysical Chemistry	Idea / basic research	Industrial / co-development partner · Pilot or clinical partner · Research collaboration	10
	COFFEE & NETWORKING BREAK				
06	**Romana Halová** CEITEC, NCBR	Research tools & platforms	Idea / basic research	Industrial / co-development partner · Research collaboration	11
07	**Martin Mňahončák** TENENET o.z.	Care	Proof of concept in the lab	Industrial / co-development partner · Research collaboration	12
08	**Lýdia Lukyová** GENETON s.r.o.	Diagnostics	Proof of concept in the lab	Pilot or clinical partner · Research collaboration	13
09	**Pavle Križan** CEITEC, NCBR, MUNI	Consumable and Service Provider	Proof of concept in the lab	Investment · Licensing partner · Industrial / co-development partner	14
10	**Zuzana Bednáriková** Institute of Experimental Physics, Slovak Academy of Sciences	Therapy	Idea / basic research	Research collaboration	15

Loschmidt Laboratories, Masaryk University

Research group · Research tools & platforms



David Damborský

Researcher

E-mail david.damborsky@fnusa.cz
LinkedIn linkedin.com/in/david-damborsky
Web loschmidt.chemi.muni.cz/peg

Protein binders on demand — designed, expressed and measured in one place

THE PROBLEM

Alzheimer's: 55M people today, 139M by 2050. Teams targeting ApoE have no reagent that suppresses its aggregation, and no antibody reliably separates ApoE4 from ApoE3. Each new binding reagent costs 6–12 months, and most candidates fail.

OUR SOLUTION

We design binders computationally, express them cell-free and measure affinity in one lab, so a new target becomes a measured binder in weeks instead of 6–12 months. L36 and L29 suppress ApoE aggregation.

WHO IT IS FOR

Diagnostics developers, pharma and biotech running neurodegeneration programmes, and academic labs needing a binder no catalogue sells.

STAGE

- ○ Idea / basic research
- ● **Proof of concept in the lab**
- ○ Validated prototype / preclinical
- ○ Clinical validation / pilot with users
- ○ On the market

IP status: **Not protected yet**

WE ARE LOOKING FOR

Industrial / co-development partner

Research collaboration · **Business mentoring**

We are looking for an industrial partner to bring us targets with no good binders: we design, express and measure candidates against it and return the measured hits in three months.

MultiplexDX International

Company | Research tools & platforms



Sarah Anne Barnes

Scientist and Industrial PhD Student

E-mail barnes@multiplexdx.com
LinkedIn linkedin.com/in/sarah-barnes-016b42175
Web multiplexdx.com/post/matching-grant-to-addit-ce-project

Unlocking early neurodegenerative disease diagnosis using new non-invasive biomarkers

THE PROBLEM

Lack of accurate tests hinders early neurodegenerative disease diagnosis. Current diagnosis involves costly, invasive and subjective tests that are reliable only after symptoms present. Late diagnosis prevents meaningful implementation of preventative measures.

OUR SOLUTION

We developed a method to detect changes in miRNA biomarkers in blood and other bodily fluids, which could be used to detect Alzheimer's (AD) and other neurodegenerative diseases years before the first symptoms. Our method identifies three times more miRNAs than the next best commercial competitor.

WHO IT IS FOR

Patients gain non-invasive early diagnosis, while industrial investors gain a flexible platform with diverse disease and research market potential.

STAGE

- ○ Idea / basic research
- ○ Proof of concept in the lab
- ● **Validated prototype / preclinical**
- ○ Clinical validation / pilot with users
- ○ On the market

IP status: **Patent application filed**


WE ARE LOOKING FOR

- **Investment**
- **Industrial / co-development partner**
- **Business mentoring**

We seek an external commercial partner or investors with the interest and expertise to assist with the necessary steps to take this working method from the bench to a certified commercial product.

Institute of Neuroimmunology SAS

Research group | Research tools & platforms



Ondrej Cehlár

Senior Scientist

E-mail ondrej.cehlar@savba.sk
LinkedIn linkedin.com/in/ondrej-cehlar-523886167
Web niu.sav.sk

Biophysical and structural characterization of biologics

THE PROBLEM

Presence of contaminants in biological preparations leads to dangerous side effects.

OUR SOLUTION

We characterize biologicals for size distribution and homogeneity, and characterize their binding affinity and 3D structure.

WHO IT IS FOR

Small and medium biotech companies, academic groups.

STAGE

- Idea / basic research
- Proof of concept in the lab
- Validated prototype / preclinical
- **Clinical validation / pilot with users**
- On the market

IP status: **Not applicable**

WE ARE LOOKING FOR

Research collaboration

You can contact us if you need to characterize your biomacromolecules.

Slovenská Alzheimerova spoločnosť

Non-profit organisation | Family and patients support



Katarína Kiseľáková

Vice-Chair

E-mail kiselakova@alzheimer.sk
Web alzheimer.sk

From Support to Impact: Making Life Better With Dementia

THE PROBLEM

People with dementia and their families face stigma, fragmented care and limited support. Existing services often fail to meet their needs, leaving families feeling alone. The Slovak Alzheimer's Society provides guidance, support and voice for them.

OUR SOLUTION

We support people living with dementia and their families through counselling, education, practical guidance and peer support. We raise awareness, fight stigma and advocate for better care, helping families navigate the challenges of dementia with dignity, confidence and less isolation.

WHO IT IS FOR

People with dementia, family caregivers, healthcare professionals, social care providers, municipalities and funders supporting dementia care.

STAGE

- Idea / basic research
- Proof of concept in the lab
- Validated prototype / preclinical
- Clinical validation / pilot with users
- **On the market**

IP status: **Know-how / trade secret**

WE ARE LOOKING FOR

Investment | Research collaboration | Business mentoring

We seek investors, grant funders and partners to expand dementia support, education programmes and awareness campaigns across Slovakia.

CEITEC/SciF, Masaryk University

Research group | Structural Biology & Biophysical Chemistry



Jozef Hritz

PI

E-mail jozef.hritz@ceitec.muni.cz
Web ncbr.muni.cz/en/research/research-groups/protcan

Disease-Specific Protein Structures: New Class of Biomarkers in Neurodegeneration

THE PROBLEM

Different neurodegenerative diseases are linked to distinct protein fibril structures. However, how functional monomeric proteins transform into these disease-specific forms remains poorly understood, limiting diagnostic and therapeutic development.

OUR SOLUTION

We provide molecular-level characterization of proteins, biomarkers and therapeutic targets. Our expertise includes aggregation and phase-separation studies, as well as binding epitope mapping for antibodies and nanobodies using integrated experimental and computational approaches.

WHO IT IS FOR

Academic, clinical, biotech, pharma and investment partners developing biomarkers, antibodies or neurodegeneration-related therapeutics.

STAGE

- (●) **Idea / basic research**
- ( ) Proof of concept in the lab
- ( ) Validated prototype / preclinical
- ( ) Clinical validation / pilot with users
- ( ) On the market

IP status: **Not applicable**

WE ARE LOOKING FOR

- **Industrial / co-development partner**
- **Pilot or clinical partner**
- **Research collaboration**

We seek collaborators developing protein biomarkers, antibodies or therapeutic targets to characterize their structure, binding epitopes, interactions and aggregation pathways.

CEITEC, NCBR

Research group | Research tools & platforms



Romana Halová

PhD Student

E-mail romana.halova@ceitec.muni.cz
Web ncbr.muni.cz/en/research/research-groups/protcan

Making Alzheimer's Research More Predictive and Reproducible

THE PROBLEM

Researchers and biotech companies need better models of Tau pathology. Current Tau reagents often lack disease-relevant modifications, reducing translational value and slowing the development of new Alzheimer's therapies.

OUR SOLUTION

We produce different Tau proteins, including forms modified by Alzheimer's-related kinases and able to form fibrils. Our proteins are made with high purity and designed to behave the same way from batch to batch, helping researchers obtain more reliable and consistent results.

WHO IT IS FOR

Therapeutic developers, diagnostic companies, research groups.

STAGE

- (●) **Idea / basic research**
- ( ) Proof of concept in the lab
- ( ) Validated prototype / preclinical
- ( ) Clinical validation / pilot with users
- ( ) On the market

IP status: **Not protected yet**

WE ARE LOOKING FOR

Industrial / co-development partner

Research collaboration

We are looking for Alzheimer's researchers, diagnostic companies, and drug developers to share their needs, test our Tau protein samples, and help us build a product that best supports their work.

TENENET o.z.

Non-profit organisation | Care



Martin Mňahončák

Director for Strategy and Development

E-mail martin.mnahoncak@tenenet.sk
LinkedIn linkedin.com/in/martin-mňahončák-phd-mba-mph-616931a2
Web tenenet.sk

Mental health services provider

THE PROBLEM

No connected health and social care in the field of mental health care. No relevant data collection and missing SDOH data.

OUR SOLUTION

We started to provide licensed services in health care, social care and special education to support our clients and patients as comprehensively as possible. By collecting SDOH data, we are able to see all missing information and see the impact of social care and other support on health care.

WHO IT IS FOR

Patients, clients and families.

STAGE

- ○ Idea / basic research
- ● **Proof of concept in the lab**
- ○ Validated prototype / preclinical
- ○ Clinical validation / pilot with users
- ○ On the market

IP status: **Not applicable**

WE ARE LOOKING FOR

Industrial / co-development partner

Research collaboration

We would like to spread SDOH data collection into EU health care.

GENETON s.r.o.

Company | Diagnostics



Lýdia Lukyová

PhD Student

E-mail lydia.lukyova@geneton.sk
LinkedIn sk.linkedin.com/company/geneton-s-r-o-
Web geneton.sk/en

Alzheimer's in Blood: What are we missing? Two Layers: cfDNA meets proteomics

THE PROBLEM

Alzheimer's disease develops years before clear symptoms emerge. While current blood biomarkers and tests provide valuable insights, they still fall short of detecting the disease early and accurately enough.

OUR SOLUTION

We aim to combine cfDNA analysis and advanced blood protein testing to enable earlier and more accurate Alzheimer's risk assessment, track disease progression over time, and lay the foundation for a more effective, scalable blood-based screening solution.

WHO IT IS FOR

Clinicians, patients.

STAGE

- ○ Idea / basic research
- ● **Proof of concept in the lab**
- ○ Validated prototype / preclinical
- ○ Clinical validation / pilot with users
- ○ On the market

IP status: **Know-how / trade secret**

WE ARE LOOKING FOR

Pilot or clinical partner

Research collaboration

We seek clinical and research partners with longitudinal AD and neurodegenerative cohorts to validate our combined cfDNA–proteomics approach, offering cfDNA expertise and Alamar proteomics services.

CEITEC, NCBR, MUNI

Research group | Consumable and Service Provider



Pavle Križan

PhD Student

E-mail pavle.krizan@ceitec.muni.cz

A Perfect Fit: Alpha-Synuclein Research Solutions According To Your Custom Needs

THE PROBLEM

Research groups and biotech companies researching alpha-synuclein related diseases have a problem with standardization of how this protein behaves. This is due to poor quality control and lack of standards in protein production.

OUR SOLUTION

We provide custom alpha-synuclein solutions based on individualized consultations with clients. We produce the protein in forms that are scarcely available on the market and perform extensive quality control to ensure the protein will behave in a predictable manner.

WHO IT IS FOR

Research groups and biotech companies.

STAGE

- ○ Idea / basic research
- ● **Proof of concept in the lab**
- ○ Validated prototype / preclinical
- ○ Clinical validation / pilot with users
- ○ On the market

IP status: **Not protected yet**

WE ARE LOOKING FOR

Investment | **Licensing partner** | **Industrial / co-development partner**

We are looking for new customers and investment opportunities to expand our business.

Institute of Experimental Physics, Slovak Academy of Sciences

Research group | Therapy



Zuzana Bednáriková

Researcher

E-mail bednarikova@saske.sk
LinkedIn linkedin.com/in/zuzana-bednarikova-1a31b3410
Web amyllab.saske.sk

From Molecular Mechanisms to Therapeutic Opportunities for Neurodegeneration

THE PROBLEM

Amyloid aggregation contributes to neurodegenerative diseases, yet its mechanisms and toxicity remain incompletely understood. Researchers need better methods to characterize aggregation and evaluate potential inhibitors.

OUR SOLUTION

We combine quantitative amyloid aggregation kinetics, biophysical characterization and advanced AFM imaging to investigate aggregation mechanisms and evaluate candidate inhibitors, including small molecules, peptides and proteins.

WHO IT IS FOR

Labs, pharma/tech companies.

STAGE

- (●) **Idea / basic research**
- ( ) Proof of concept in the lab
- ( ) Validated prototype / preclinical
- ( ) Clinical validation / pilot with users
- ( ) On the market

IP status: **Not applicable**

WE ARE LOOKING FOR

Research collaboration

We are looking for biotech/pharma companies and neuroscience research groups to collaborate and combine our expertise with their compounds, disease models or complementary AI/ML technologies.

YOUR NEXT STEP · WORKSHOP · 25 NOVEMBER 2026 · BRNO

How to Talk About Your Research with Investors

Turn your science into a pitch investors understand – in one afternoon.

Want to keep working on your pitch – or be on stage next time? Join a hands-on follow-up workshop with practice, instant feedback and an investor's perspective.

What you will take away

1. **Communicate the value of your research**
   Problem, solution, who benefits – and a pitch deck structure made for researchers.

2. **Build your 120-second pitch on the spot**
   No slides needed. Pitch to the group and get instant feedback.

3. **See research through investors' eyes**
   Panel with an investor and two founders who took their science into business.

FREE · IN ENGLISH · ONLY 50 SEATS · NO BUSINESS EXPERIENCE NEEDED

For researchers from PhD students to group leaders.
Organised together with BridgeTTe and JIC.

25 November 2026

12:30 – 18:00

JIC Startup Hub
Purkyňova 127, Brno

Scan & register
Places are limited

jic.cz/cz/workshop-how-to-talk-about-your-research-with-inve

ADDIT-CE

This event has received funding from the European Union's Horizon Europe program under Grant Agreement No. 101087124.

www.addit-ce.ceitec.cz

If you have any questions:
events@multiplexdx.com

ADDIT-CE NeuroConnect Meetup · 2nd edition
5 November 2026 · MultiplexDX, Comenius University Science Park, Ilkovičova 8, Bratislava



Multiplex DX

BioVendor Group

JIC

BridgeTTe

MUNI

ADDIT-CE

Funded by the European Union